Yasheng Pharmaceutical Announces 2021 Interim Results: Outstanding Clinical Advantages of Important Products and Major Breakthroughs in External Cooperation

Suzhou, China and Rockville, Maryland, USA, August 24, 2021-Ascent Pharmaceuticals (6855.

During the reporting period, the company made great progress in clinical development, foreign cooperation, and patent layout.

Adhere to the global innovation positioning and comprehensively advance clinical development

In the first half of 2021, Yasheng Pharmaceutical's investment in innovation continued to increase, with R&D expenditures of approximately RMB 318 million, an increase of 26.

During the reporting period, the clinical development of Yasheng Pharmaceutical's research products was rapidly advancing

As the first locally developed Bcl-2 selective inhibitor to enter the clinical stage in China, lisaftoclax (APG-2575) started a research and development exploration for a new indication in June this year, and was awarded the U.

It is worth noting that the number of orphan drug certifications obtained by Yasheng Pharmaceutical has reached a new high.

Focusing on clinical value, clinical advantages of important varieties have been verified

As one of the most advanced companies in the world in the research and development of new drugs in the apoptosis pathway, Ascent Pharmaceuticals has made remarkable progress in the clinical research of many important species in the field of apoptosis.

The Bcl-2 inhibitor APG-2575, an important product of Ascent Pharmaceuticals’ apoptosis pipeline, announced an oral report at the 2021 ASCO annual meeting in the form of relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphoid The latest data from the first human trials in patients with cellular lymphoma (CLL/SLL) and other hematological malignancies

Another important species in the apoptosis pipeline, MDM2-p53 inhibitor APG-115, also announced the unresectable/metastatic effect of combined pembrolizumab for immuno-oncology drug treatment failure at the 2021 ASCO annual meeting in the form of an oral report.

A number of major cooperations have been reached, and extension development has been actively promoted

During the reporting period, Yasheng Pharmaceutical and Cinda Biotech reached a major strategic cooperation, creating a brand-new cooperation model for domestic innovative pharmaceutical companies

While reaching domestic cooperation to create a win-win path, Yasheng Pharmaceuticals is also actively seeking overseas cooperation to promote global innovation in research products, and has reached a cooperative research and development agreement (CRADA) with the world's leading academic institution, the National Cancer Institute (NCI), The two parties will cooperate in clinical and non-clinical development for the original dual-target Bcl-2/Bcl-xL inhibitor pelcitoclax (APG-1252) of Ascent Pharmaceuticals

It is worth mentioning that Yasheng Pharmaceutical has once again received a milestone payment from its global strategic partner UNITY Biotechnology.

Steadily promote commercialization and industrialization to help products go to market

In order to further cooperate with the company's commercialization and globalization, the global headquarters, R&D center, and industrial base of Yasheng Pharmaceutical started construction in November 2019, and the construction of facilities is progressing rapidly.

Dr.

In the future, we will continue to vigorously promote the commercialization of HQP1351 and achieve the company's first product launch as soon as possible; at the same time, we will continue to accelerate the global clinical development of the species under research, adhere to the global innovation positioning, and adhere to the practice of'solving the unsatisfied patients in China and even the world.

About Yasheng Pharmaceutical

Ascent Pharmaceuticals is an original innovative drug research and development company based in China and facing the world in the clinical development stage.

Ascent Pharmaceuticals has a self-constructed protein-protein interaction targeted drug design platform, and is at the forefront of new drug development in the apoptosis pathway in the world
.
The company has established 8 new class 1 small molecule drug product pipelines that have entered the clinical development stage, including inhibitors that inhibit key proteins in the apoptosis pathway such as Bcl-2, IAP, or MDM2-p53; a new generation of drugs that have emerged in cancer treatment Inhibitors of kinase mutants, etc.
, are the only innovative company in the world that has clinically developed varieties in the field of key proteins in the apoptosis pathway
.
The company is currently conducting more than 40 phase I/II clinical trials in China, the United States, Australia and Europe
.
The company has undertaken a number of major national science and technology projects, including 5 special projects for "Major New Drug Development", including 1 "Enterprise Innovative Drug Incubation Base" and 4 "Innovative Drug Research and Development", and another special project for "Prevention and Control of Major Infectious Diseases".

.
The core variety HQP1351, which is used to treat drug-resistant chronic myeloid leukemia, has been submitted for new drug marketing applications in China and has been included in the priority review and breakthrough therapy varieties
.
This variety has also obtained the U.
S.
FDA's fast track review and orphan drug certification
.
Up to now, the company has 4 new drugs under development that have obtained 12 FDA orphan drug qualification certifications
.

Relying on strong R&D capabilities, Yasheng Pharmaceuticals has deployed intellectual property rights worldwide, and has cooperated with leading biotechnology and pharmaceutical companies such as UNITY, MD Anderson, Mayo Medical Center, Dana-Farber Cancer Institute, Merck, AstraZeneca, etc.
Companies and academic institutions have reached a global partnership
.
The company has established an international talent team with rich experience in original innovative drug research and development and clinical development.
At the same time, the company is building a late-stage commercial production and marketing team with high standards
.
Yasheng Pharmaceutical will continue to improve its research and development capabilities, accelerate the progress of the clinical development of the company's product pipeline, and truly implement the mission of "solving the unmet clinical needs of patients in China and even the world" to benefit more patients
.